<DOC>
	<DOCNO>NCT02670720</DOCNO>
	<brief_summary>This open-label study design evaluate long-term safety prophylactic avoralstat ( 500 mg three time daily ) give approximately 150 patient hereditary angioedema ( HAE ) duration 72 week . The study also evaluate long-term efficacy impact quality life avoralstat prophylactic treatment .</brief_summary>
	<brief_title>Open-label , Long-term Safety Study Avoralstat Subjects With Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>Males nonpregnant , nonlactating female age â‰¥ 18 year . Provide write , informed consent . Prior completion avoralstat therapeutic study OR confirm diagnosis HAE Type 1 HAE Type 2 . Access appropriate medication treatment acute HAE attack . Adequate contraception . Females pregnant breast feeding . Clinically significant medical condition medical history . Abnormal screen ECG , laboratory urinalysis find clinically significant . Investigational drug exposure within 30 day ( except avoralstat ) . History current alcohol drug abuse . HIV active HBV HCV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>BCX4161</keyword>
	<keyword>avoralstat</keyword>
	<keyword>HAE</keyword>
	<keyword>hereditary angioedema</keyword>
	<keyword>prophylaxis</keyword>
</DOC>